Pular para o conteúdo principal
Ranking Invest

VALN - Valneva SE

Segmento: HealthcareValneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Análise Ranking Invest

Valuation estimado
-$ 109.54 Mi
Valor de Mercado
$ 635.85 Mi
Desconto (AV)-680.5%
IVR
-0.17A companhia vale -0,17 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.44O valuation alternativo equivale a -44% do valor de mercado da companhia.
MLL
-0.44O lucro líquido dos controladores em 16 trimestres equivale a -44% do valor de mercado.
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 175.25 Mi

Dívida Líquida

$ 58.16 Mi

L4T

-$ 80.39 Mi

MM4T

-43.57%

Indicadores Básicos

ROE

-45.87%

Índices de Previsibilidade

Receita Líquida

F0.46

Lucro

F2.21

Margem

F2.75

Índices de Tendência

Receita Líquida

D-0.90

Lucro

D1.40

Margem

C4.23

Índices de Endividamento

DIV/PAT

0.33

DIV/L4T

-0.72

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.